상세 보기
An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) plus chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo plus trastuzumab ± pembro in first-line metastatic HER2+gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.
- Shitara, Kohei;
- Shen, Lin;
- Lee, Jeeyun;
- Hoff, Paulo Marcelo;
- Smyth, Elizabeth Catherine;
- 외 5명
Citations
WEB OF SCIENCE
0- 제목
- An open-label, randomized, multicenter, phase 3 study of trastuzumab deruxtecan (T-DXd) plus chemotherapy (chemo) ± pembrolizumab (pembro) versus chemo plus trastuzumab ± pembro in first-line metastatic HER2+gastric or gastroesophageal junction (GEJ) cancer: DESTINY-Gastric05.
- 저자
- Shitara, Kohei; Shen, Lin; Lee, Jeeyun; Hoff, Paulo Marcelo; Smyth, Elizabeth Catherine; Barrios, Daniel; Kobayashi, Kojiro; Okuda, Yasuyuki; Kamio, Takahiro; Janjigian, Yelena Y.
- 발행일
- 2026-01
- 유형
- Meeting Abstract
- 권
- 44
- 호
- 2_SUPPL
- 페이지
- TPS468 ~ TPS468